Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpharadin (Radium-223) in CRPC Bone Metastases
NCT02135484Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2014
- Primary completion
- Nov 2020
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Open-label, single-arm trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Survival at 3.6 years. Started Sep 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02135484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135484.